At this historic point in time, we had the opportunity to investigate changes during a new highly effective CFTR-modulator combination, which in the CF community is seen as a new era in therapy for pwCF carrying a F508del mutation (Heijerman et al., 2019; Middleton et al., 2019), the most frequent CFTR-mutation in Europe, UK, US, and Australia. The gene discussed is CFTR; the disease is cystic fibrosis.